kairoby Opportune Labs

Gonadorelin

A form of gonadotropin-releasing hormone used in specialist reproductive care and research. The pattern of hormone signalling is central to the evidence; results from a pulsatile pump cannot validate arbitrary intermittent add-on use.

Usually compoundedHuman fertility evidence exists for specific hypothalamic conditions and controlled pulsatile delivery.
Kairo editorial · Sources reviewed September 9, 20265 sources
On this page
  1. Overview
  2. What the evidence shows
  3. Safety
  4. Common questions
  5. Questions for your clinician
  6. Sources

Typically prepared by a compounding pharmacy under the direction of a licensed healthcare professional — not an FDA-approved finished product in this form.

Overview

Product & regulatory status

Prescription/specialist reproductive hormone. Authorization and availability must be checked for the exact human product; compounded versions are not FDA-approved finished drugs.

Restoring a missing signal

Pulsatile GnRH supplies a hypothalamic signal that drives pituitary gonadotropin release in appropriately selected patients. [1]

What the evidence shows

Hypothalamic amenorrhea cohort

A single-centre retrospective study followed 66 women with functional hypothalamic amenorrhea receiving a pulsatile GnRH pump. Across 212 cycles, ovulation occurred in 96%; live birth per treatment was 65.9%. These are selected-patient observational results, not a randomized guarantee. [1]

Male evidence concerns a specific disorder

A clinical study compared a pulsatile gonadorelin pump with gonadotropin therapy in men with congenital hypogonadotropic hypogonadism. Its spermatogenesis findings concern replacement of deficient signalling, not proof that a routine TRT add-on preserves fertility. [2]

What remains unknown

Whether a proposed preparation and exposure pattern reproduce the studied physiology must be established. Fertility depends on more than one hormone result.

Safety

Reproductive outcomes require monitoring

The female cohort included miscarriage and a twin pregnancy despite generally favorable outcomes. Specialist treatment does not eliminate reproductive risk. [1]

Product uncertainty

Compounded-drug quality and safety are not established through FDA premarket approval. [3]

Human product and delivery system

The cited fertility evidence is tied to a specialist pump system. Veterinary products and research vials are not substitutes for that evidence. [1]

Understanding product quality

Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [4]

When to seek urgent help

Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [5]

A starting point for discussion

This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.

Common questions

Is gonadorelin the same as HCG?

No. Gonadorelin acts through pituitary signalling; HCG has LH-like activity at the gonads. Their evidence is not interchangeable.

Can pump research justify any gonadorelin schedule?

No. The delivery pattern is a defining feature of the studied treatment, not an incidental detail.

Questions for your clinician

Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?

Sources

  1. Quaas et al.: pulsatile GnRH in hypothalamic amenorrheaJournal of Assisted Reproduction and Genetics, 2022; retrospective single-centre cohort of 66 patients and 212 treatment cycles.
  2. Pulsatile gonadorelin pump and male spermatogenesis2018 primary clinical comparison in congenital hypogonadotropic hypogonadism; not a study of intermittent add-on use in routine TRT.
  3. FDA: compounding questions and answersFDA explanation of compounded-drug approval and quality differences; accessed September 9, 2026.
  4. Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
  5. AnaphylaxisMedlinePlus · recognizing an emergency

Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.